Category: biotech

.Merck &amp Co. is actually paying $700 million in advance to test Amgen in a blood stream cancer cells market. The deal will definitely offer

.Merck &amp Co. has actually gotten options on 2 Evaxion Biotech injection candidates, paying for $3.2 thousand and also hanging much more than $1 billion

.Merck &amp Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has actually racked up a small triumph. The drugmaker’s Daiichi

.A phase 3 test of Daiichi Sankyo and also Merck &amp Co.’s HER3-directed antibody-drug conjugate (ADC) has attacked its own key endpoint, improving programs to

.Gilead Sciences as well as Merck &amp Co. have actually helped their once-weekly HIV mix treatment past yet another milestone, linking the beverage to continual

.MBX has actually elaborated plans to absorb over $136 million from its own IPO as the biotech hopes to carry a prospective challenger to Ascendis

.MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which submitted its own documentation weeks after increasing $63.5 thousand privately, is

.Observing an unsatisfactory showing for Lykos Rehabs’ MDMA applicant for trauma at a recent FDA advising board conference, the other footwear possesses dropped.On Friday, the

.Psychopharmacology has actually pulled three short articles regarding midstage clinical trial records analyzing Lykos Therapies’ investigational MDMA candidate for addressing post-traumatic stress disorder (PTSD). The

.Lykos Therapeutics may possess lost three-quarters of its team back the FDA’s denial of its MDMA candidate for trauma, however the biotech’s brand-new management feels